Skip to main content
Back
TRSBF logo

3SBio Inc.

Data quality: 100%
TRSBF
OTC Healthcare Biotechnology
$2.58
$0.00 (0.00%)
Mkt Cap: 6.09B
Day Range
$2.58 $3.56
52-Week Range
$0.83 $4.74
Volume
1,000
50D / 200D Avg
$2.91 / $3.49
Prev Close
$2.58

Price History

Financial Trends

Peer Comparison

vs Healthcare sector median (626 peers)

Metric Stock Sector Median
P/E 2.9 0.4
P/B 0.4 2.9
ROE % 14.2 3.8
Net Margin % 23.0 3.9
Rev Growth 5Y % 13.0 10.0
D/E 0.2 0.2

Key Takeaways

Revenue grew 12.99% annually over 5 years — strong growth
Earnings grew 34.93% over the past year
ROE of 14.19% — decent returns on equity
Net margin of 22.95% shows strong profitability
Debt/Equity of 0.23 — conservative balance sheet
Generating 2.24B in free cash flow

Growth

Revenue Growth (5Y)
12.99%
Revenue (1Y)16.53%
Earnings (1Y)34.93%
FCF Growth (3Y)36.19%

Quality

Return on Equity
14.19%
ROIC10.79%
Net Margin22.95%
Op. Margin29.99%

Safety

Debt / Equity
0.23
Current Ratio1.71
Interest Coverage14.31

Valuation

P/E Ratio
2.91
P/B Ratio0.39
EV/EBITDA2.79
Dividend Yield0.04%

All Fundamental Metrics

Growth
Revenue Growth (1Y) 16.53% Revenue Growth (3Y) 15.23%
Earnings Growth (1Y) 34.93% Earnings Growth (3Y) 4.46%
Revenue Growth (5Y) 12.99% Earnings Growth (5Y) 25.76%
Profitability
Revenue (TTM) 9.11B Net Income (TTM) 2.09B
ROE 14.19% ROA 8.63%
Gross Margin 85.95% Operating Margin 29.99%
Net Margin 22.95% Free Cash Flow (TTM) 2.24B
ROIC 10.79% FCF Growth (3Y) 36.19%
Safety
Debt / Equity 0.23 Current Ratio 1.71
Interest Coverage 14.31 Dividend Yield 0.04%
Valuation
P/E Ratio 2.91 P/B Ratio 0.39
P/S Ratio 0.67 PEG Ratio 0.19
EV/EBITDA 2.79 Dividend Yield 0.04%
Market Cap 6.09B Enterprise Value 7.62B

Income Statement

Annual, most recent first

Income statement data, annual, most recent first
Metric FY2024 FY2023 FY2022 FY2021 FY2020
Revenue 9.11B 7.82B 6.86B 6.38B 5.59B
Net Income 2.09B 1.55B 1.92B 1.65B 835.79M
EPS (Diluted) 0.85 0.62 0.74 0.62 0.33
Gross Profit 7.83B 6.64B 5.67B 5.28B 4.52B
Operating Income 2.73B 2.46B 2.07B 1.83B 1.46B

Balance Sheet

Annual, most recent first

Balance sheet data, annual, most recent first
Metric FY2024 FY2023 FY2022 FY2021 FY2020
Total Assets 24.21B 23.63B 21.99B 19.21B 17.68B
Total Liabilities 6.18B 7.11B 6.59B 4.55B 4.58B
Shareholders' Equity 15.44B 14.03B 12.96B 12.23B 10.69B
Total Debt 3.55B 4.84B 4.52B 2.63B 2.91B
Cash & Equivalents 2.02B 2.69B 2.15B 2.80B 3.09B
Current Assets 9.35B 9.19B 9.76B 7.79B 6.68B
Current Liabilities 5.46B 3.73B 1.79B 1.42B 1.45B

Strategy Scores

This stock passed the criteria for 4 strategies

Score = fit strength (0–100)
Rank = position among all matches
Custom Cash Flow Compounder
#514 of 1024
45
Custom Deep Value Investing (Seth Klarman)
#39 of 820
72
Growth Price/Sales Ratio Focus (Ken Fisher)
#246 of 616
42
Value Defensive Investing (Benjamin Graham)
#11 of 708
76

Recent Activity

Entered Cash Flow Compounder
Mar 24, 2026
Entered Deep Value Investing (Seth Klarman)
Mar 24, 2026
Entered Price/Sales Ratio Focus (Ken Fisher)
Mar 24, 2026
Entered Defensive Investing (Benjamin Graham)
Mar 24, 2026